Literature DB >> 3828800

The characterization of [3H]sulpiride binding sites in rat striatal membranes.

J Imafuku.   

Abstract

The characteristics of [3H]sulpiride binding to the D2 dopamine receptor in rat striatal membranes were examined under several conditions. In the absence of sodium ions, the specific binding of [3H]sulpiride could not be detected. In the direct binding experiment, at 25 degrees C, the affinity of [3H]sulpiride for D2 receptors was increased in a dose-dependent manner of sodium ions whereas magnesium ions have opposite effects on an affinity of [3H]sulpiride binding. The lowering incubation temperature (4 degrees C) also produced a further increase in affinity of the ligand. Under all conditions, [3H]sulpiride labeled a single homogenous site of the receptor. On the other hand, the result from quantitative analysis of agonist/[3H]sulpiride competition curves indicated an existence of high (RH) and low (RL) affinity states for agonists and the proportion of two-affinity states was modulated by guanosine triphosphate (GTP), magnesium ions and lowering temperatures. GTP, together with sodium ions, caused a full conversion of RH to RL, while an increase in the affinity for agonists with a partial conversion of RL to RH could be induced by magnesium ions at 25 degrees C. At a lower (4 degrees C) temperature, the agonist competition curve indicated an existence of a single agonist low-affinity state (RL) and then, the effects of GTP and magnesium ions in the agonist affinity observed at 25 degrees C were abolished. These results can be incorporated into a two-step, ternary complex model involving an inhibitory guanine nucleotide binding protein for the agonist and antagonist interaction with D2 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3828800     DOI: 10.1016/0006-8993(87)90040-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Expression and distribution of all dopamine receptor subtypes (D(1)-D(5)) in the mouse lumbar spinal cord: a real-time polymerase chain reaction and non-autoradiographic in situ hybridization study.

Authors:  H Zhu; S Clemens; M Sawchuk; S Hochman
Journal:  Neuroscience       Date:  2007-09-12       Impact factor: 3.590

Review 2.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

3.  Interactions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriers.

Authors:  Jan Walkembach; Michael Brüss; Bernd W Urban; Martin Barann
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

4.  Neuroleptic malignant syndrome due to sulpiride.

Authors:  K Kashihara; K Ishida
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-08       Impact factor: 10.154

5.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

6.  Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice.

Authors:  Stefan Clemens; Shawn Hochman
Journal:  J Neurosci       Date:  2004-12-15       Impact factor: 6.167

7.  Quantitative comparison of functional screening by measuring intracellular Ca2+ with radioligand binding at recombinant human dopamine receptors.

Authors:  Matthias U Kassack
Journal:  AAPS PharmSci       Date:  2002

8.  The peripheral dopamine 2 receptor antagonist domperidone attenuates ethanol enhancement of dopamine levels in the nucleus accumbens.

Authors:  James Daniel Obray; Eun Young Jang; Anneke M Klomp; Christina A Small; Aaron P Richardson; Joshua J LeBaron; Jin Gyeom Lee; Jordan T Yorgason; Chae Ha Yang; Scott C Steffensen
Journal:  Alcohol Clin Exp Res       Date:  2022-02-01       Impact factor: 3.455

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.